These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1553 related articles for article (PubMed ID: 24182642)

  • 1. Managing pulmonary embolism from presentation to extended treatment.
    Cohen AT; Dobromirski M; Gurwith MM
    Thromb Res; 2014 Feb; 133(2):139-48. PubMed ID: 24182642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
    Prandoni P
    Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Kearon C; Kahn SR; Agnelli G; Goldhaber S; Raskob GE; Comerota AJ
    Chest; 2008 Jun; 133(6 Suppl):454S-545S. PubMed ID: 18574272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective diagnosis and treatment of pulmonary embolism: Improving patient outcomes.
    Meyer G
    Arch Cardiovasc Dis; 2014; 107(6-7):406-14. PubMed ID: 25023859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study.
    Prandoni P
    Eur J Haematol; 2012 Oct; 89(4):281-7. PubMed ID: 22834998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation and management of chronic pulmonary thromboembolic disease.
    Mendoza V; Scharf ML
    Hosp Pract (1995); 2011 Aug; 39(3):50-61. PubMed ID: 21881392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
    Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
    J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical analysis of 20 pregnant women with venous thromboembolic disease].
    Sun P; Dong DN
    Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):911-6. PubMed ID: 22333281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Büller HR; Agnelli G; Hull RD; Hyers TM; Prins MH; Raskob GE
    Chest; 2004 Sep; 126(3 Suppl):401S-428S. PubMed ID: 15383479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
    Lefebvre P; Coleman CI; Bookhart BK; Wang ST; Mody SH; Tran KN; Zhuo DY; Huynh L; Nutescu EA
    J Med Econ; 2014 Jan; 17(1):52-64. PubMed ID: 24156243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
    Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New direct oral oral anticoagulants (DOACs) - indications of DOACs].
    Darius H
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2014 Mar; 49(3):182-90; quiz 191. PubMed ID: 24711238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulants as alternative treatment options for the effective long-term treatment of patients with pulmonary embolism in primary care: a review.
    Toth PP
    Ann Med; 2014 Sep; 46(6):341-52. PubMed ID: 24888386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interventional approaches in VTE treatment (vena cava filters, catheter-guided thrombolysis, thrombosuction).
    Imberti D; Maraldi C; Gallerani M
    Semin Respir Crit Care Med; 2012 Apr; 33(2):176-85. PubMed ID: 22648490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
    van Bellen B; Bamber L; Correa de Carvalho F; Prins M; Wang M; Lensing AW
    Curr Med Res Opin; 2014 May; 30(5):829-37. PubMed ID: 24432872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
    Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
    Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute pulmonary embolism treatment with rivaroxaban results in a shorter duration of hospitalisation compared to standard therapy: an academic centre experience.
    Paczyńska M; Kurnicka K; Lichodziejewska B; Goliszek S; Dzikowska-Diduch O; Sobieraj P; Burzyński Ł; Kostrubiec M; Pruszczyk P; Ciurzyński M
    Kardiol Pol; 2016; 74(7):650-6. PubMed ID: 26779849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.